Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PMGC Holdings ( (ELAB) ) has issued an announcement.
On February 18, 2026, NorthStrive Biosciences, a subsidiary of PMGC Holdings, filed ten new U.S. patent applications to extend its EL-22 and EL-32 technologies into animal health and agricultural markets across livestock, aquaculture and poultry. The filings cover uses aimed at stimulating new muscle growth and higher muscle yield per animal, as well as reducing gaseous emissions in livestock and mitigating eutrophic conditions in aquaculture systems.
The livestock applications target non-feed supplement formats intended to boost muscle tissue development and potentially lower environmental impact by cutting emissions and ruminal tympany risk. In aquaculture and poultry, the patents seek protection for approaches that could shorten time to market weight, lower energy demands and increase meat yield per bird, signaling PMGC’s move to diversify EL-22 and EL-32 from human-focused therapeutics into production efficiency and sustainability solutions for global protein supply chains.
The most recent analyst rating on (ELAB) stock is a Sell with a $2.00 price target. To see the full list of analyst forecasts on PMGC Holdings stock, see the ELAB Stock Forecast page.
Spark’s Take on ELAB Stock
According to Spark, TipRanks’ AI Analyst, ELAB is a Neutral.
The score is held down primarily by weak financial fundamentals (ongoing losses and significant cash burn) and strongly bearish technical momentum (price well below major moving averages with oversold indicators). A positive pipeline-related corporate update provides some support, but valuation is not meaningfully assessable from the provided P/E and dividend data.
To see Spark’s full report on ELAB stock, click here.
More about PMGC Holdings
PMGC Holdings Inc. is a diversified holding company that grows a portfolio of businesses through strategic acquisitions, investments and development across multiple industries. Its wholly owned subsidiary NorthStrive Biosciences Inc. is a biopharmaceutical company focused on cutting-edge aesthetic medicines, led by EL-22, an engineered probiotic aimed at preserving muscle in patients undergoing weight-loss treatments such as GLP-1 receptor agonists.
NorthStrive’s work historically centered on human aesthetic and metabolic applications, positioning the subsidiary at the intersection of obesity therapeutics and muscle preservation. PMGC’s broader mandate to seek opportunities across sectors provides a corporate umbrella that can support expansions of NorthStrive’s platform technologies into adjacent markets, including animal health and agriculture.
Average Trading Volume: 1,117,184
Technical Sentiment Signal: Sell
Current Market Cap: $1.52M
For detailed information about ELAB stock, go to TipRanks’ Stock Analysis page.